Bending Spoons Shares Jump 40% After Deal for $330 Million Berkshire Investment
Key Facts
Shares in Italy's Bending Spoons jumped 40% in early trading after the announcement of an agreement for a new $330 million investment from Berkshire Hathaway, according to Reuters and a company statement. The company announced a binding private placement agreement on October 14, 2026, with plans to use part of the new funds to acquire other companies. Bending Spoons said the investment would raise Berkshire's equity stake to 4% upon completion of the transaction, which remains subject to customary closing conditions. The new funding follows Berkshire's $600 million investment in the company's initial public offering in July 2026, according to the same statement. The deal makes Berkshire the sixth-largest investor in Bending Spoons, according to London Stock Exchange Group shareholder data cited by Reuters.
The private placement involves the issuance of 10 million new ordinary shares, according to Bending Spoons' filing with the U.S. Securities and Exchange Commission on the agreement. The filing set the purchase price at $33.00 per share, with the proceeds flowing to the company through the issuance of new shares. The company said it planned to allocate part of the placement proceeds to further acquisitions, supporting its continued purchases of digital companies. Commenting on expansion opportunities, acquisitions chief Francesco Patarnello said in the company statement: "Our acquisition pipeline remains strong." Bending Spoons' business model, as described in its quarterly results, involves acquiring digital businesses, implementing deep operational transformations and making continuous improvements aimed at sustainably expanding those businesses' profits.
Bending Spoons reported revenue of $704 million in the second quarter of 2026, according to results filed with the U.S. Securities and Exchange Commission. That represented an increase of 126% from the second quarter of 2025, while organic revenue growth in the second quarter of 2026 was about 3%. The company identified Tractive and WeTransfer as the largest contributors to organic growth during that period within its portfolio of digital companies. The portfolio also includes Airtable, AOL, Brightcove, Eventbrite, Evernote and Vimeo, according to Reuters, alongside Tractive and WeTransfer. Bending Spoons says it has not sold any material business since implementing its strategy, which combines corporate acquisitions with operational restructuring and continuous performance improvements.
In its assessment of the stock following the investment announcement, Mizuho maintained its outperform rating on Bending Spoons, according to Investing.com, which cited the firm. Mizuho also maintained its price target of $72.00 per share in an assessment issued after the announcement of the new Berkshire funding. Mizuho sees Berkshire as a potential partner in future deals, according to comments cited by the website on its view of the relationship between the companies. The investment comes as Berkshire has increased its exposure to technology companies under Chief Executive Greg Abel, Reuters reported. The news agency added that this push had also included artificial intelligence, in its account of the investment group's moves under Abel.
In separate news, Liquidia announced a comprehensive settlement with United Therapeutics ending all six pending lawsuits between the companies, according to its statement on the agreement. Net payments associated with the settlement total about $380.7 million, according to the amount Liquidia disclosed in its comprehensive settlement statement. The payments will be made in installments during 2026 and 2027, according to the broad schedule the company provided for the financial obligations associated with ending the disputes. Liquidia said the agreement preserves uninterrupted access to Yutrepia for patients with pulmonary arterial hypertension. The settlement thus combines an end to the pending lawsuits with continued patient access to treatment, in exchange for the payments the company specified in its announcement and regulatory filing.
Bending Spoons expected the private placement to close in the fourth quarter of 2026, according to its filing, with the agreement subject to customary closing conditions before the investment is completed. Liquidia, meanwhile, plans to provide a broader update on Yutrepia's performance during its earnings call scheduled for November, according to the settlement statement. During the same call, the company will discuss its financial position and drug development priorities, alongside the treatment's performance following the agreement with United Therapeutics. Liquidia's filing also specified $145.4 million in deferred payments to United Therapeutics, payable in two equal installments during 2027. The installments are due no later than January 31 and April 30, 2027, according to the dates in the company's filing with the U.S. Securities and Exchange Commission.